PTGS2 and colorectal cancer: The success of chemoprevention has been impressively demonstrated in epithelial malignancies, particularly breast, prostate and colorectal cancers, with the use of selective estrogen receptor modulators (SERM) (e.g., tamoxifen), 5α-reductase inhibitors (e.g., finasteride) and cyclooxygenase-2 (COX-2) inhibitors, a type of non-steroidal anti-inflammatory drug (NSAID, e.g., sulindac, aspirin, celecoxib) that inhibited the appearance of colorectal polyps in various familial colorectal cancer predisposing syndromes [10].